Organ and Tissue Transplantation and Alternatives
The global market for transplantation products, devices, and pharmaceuticals was valued at nearly $54 billion in 2010 and is projected to grow at an 8.3% compound annual growth rate (CAGR) to reach $80 billion in 2015.
SCOPE OF REPORT
This report offers forecasts, by product segment, from 2010 through 2015, including supporting analyses for projections. Product segments covered consist of solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valves) markets, along with the pharmaceuticals that accompany each market.
Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.
The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.
Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques, and pharmaceuticals are highlighted.
Profiles of more than 50 leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies’ available and emerging products.
An appendix featuring various terms and processes used in transplantation is provided at the end of the report.
This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.
Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr has worked with the publishing arms of for-profit and not-for-profit organizations for more than 25 years, and she specializes in marketing reports on the medical industry. She has contributed several reports on the medical industry for BCC, including reports on the global market for catheters, the sterilization market, reports on pediatric and eldercare markets, and her most recent report on the cardiovascular surgical industry.
- The U.S. market for organ and tissue transplantation and alternatives was worth $18.9 billion in 2007. The market is projected to grow to $20.9 billion in 2008 and $28.2 billion in 2013, representing a compound annual growth rate (CAGR) of 6.1%.
- The solid organ segment has the largest share of the market, worth $9.7 billion in 2007 and an estimated $10.5 billion in 2008. This is expected to grow at a CAGR of 5.7% to reach $13.8 billion in 2013.
- Tissue transplantation generated $9.2 billion in 2007. This should increase to $10.4 billion in 2008 and $14.3 billion in 2013, for a CAGR of 6.5%.
The organ and tissue transplantation market in the U.S. is estimated at $11.7 billion in 2005 ad is expected to rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010.
The transplantation market is estimated at just under $5 billion in 2005 and is expanding at an AAGR of 4.8%.
The fastest growing sector is small bowel (intestine) transplantation. Kidney and liver transplantation will account for 78% of the total in 2005.
The U.S. tissue transplantation market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of 5.5%, to $8.9 billion in 2010.
Tissue and organ transplantation in the U.S. was a $17.3 billion market in 2002.
This is expected to grow 18% to $20.5 billion by 2007 at an average annual rate (AAGR) of 3.5%.
The fastest growing sector is small bowel transplantation.
Kidney transplantation accounted for 59% of U.S. organ transplants in 2002.